Literature DB >> 24750661

Poor agreement between transcranial Doppler and near-infrared spectroscopy-based estimates of cerebral blood flow changes in sepsis.

Linea N Toksvang1, Ronni R Plovsing, Marie W Petersen, Kirsten Møller, Ronan M G Berg.   

Abstract

BACKGROUND: Continuous monitoring of cerebral blood flow (CBF) may be valuable in critically ill patients with sepsis. In this study, we compared spatially resolved near-infrared spectroscopy (NIRS) to transcranial Doppler ultrasound (TCD)-derived estimates of noradrenaline-associated changes in CBF in such patients.
METHODS: Mean arterial blood pressure (MAP) was elevated by increasing the noradrenaline infusion rate in eight mechanically ventilated, critically ill patients diagnosed with severe sepsis or septic shock. The associated changes in CBF were assessed by simultaneous ipsilateral NIRS (ScO(2)) and TCD (middle cerebral artery blood flow velocity, MCAv) measurements.
RESULTS: A total of fifteen simultaneous NIRS- and TCD-derived assessments of noradrenaline-associated changes in CBF were obtained. MAP was increased from 74 (median; interquartile range (IQR), 71-90) to 100 (median; IQR, 93-115) mmHg (P<0·05), which was associated with an increase in MCAv of 14% (median; IQR, 2-22; P<0·05), whereas no changes were observed in ScO(2) ; 1% (median; IQR, [-4]-3; P = 0·96). A Bland-Altman plot was used to compare the two methods and showed a poor agreement between NIRS- and TCD-derived estimates with a relative bias of 14% and limits of agreement of -18% to 45% change in CBF.
CONCLUSION: Our findings stress that TCD and NIRS cannot be used interchangeably for monitoring changes in cerebral haemodynamics in critically ill patients with sepsis receiving vasopressor treatment with noradrenaline.
© 2014 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bland-Altman; cerebral haemodynamics; near-infrared spectroscopy; noradrenaline; septic shock; severe sepsis; transcranial Doppler; vasopressor treatment

Mesh:

Substances:

Year:  2014        PMID: 24750661     DOI: 10.1111/cpf.12120

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  6 in total

1.  What is a Clinician to Do?

Authors:  Clifford S Deutschman
Journal:  Crit Care Med       Date:  2018-07       Impact factor: 7.598

2.  Cerebral Near-Infrared Spectroscopy in Adult Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation.

Authors:  Selene Pozzebon; Aaron Blandino Ortiz; Federico Franchi; Stefano Cristallini; Mirko Belliato; Olivier Lheureux; Alexandre Brasseur; Jean-Louis Vincent; Sabino Scolletta; Jacques Creteur; Fabio Silvio Taccone
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

3.  Low Dosing Norepinephrine Effects on Cerebral Oxygenation and Perfusion During Pediatric Shock.

Authors:  Meryl Vedrenne-Cloquet; Judith Chareyre; Pierre-Louis Léger; Mathieu Genuini; Sylvain Renolleau; Mehdi Oualha
Journal:  Front Pediatr       Date:  2022-07-06       Impact factor: 3.569

4.  Endothelial Dysfunction and Impaired Neurovascular Coupling Responses Precede Cognitive Impairment in a Mouse Model of Geriatric Sepsis.

Authors:  Tamas Csipo; Benjamin R Cassidy; Priya Balasubramanian; Douglas A Drevets; Zoltan I Ungvari; Andriy Yabluchanskiy
Journal:  Front Aging Neurosci       Date:  2021-05-14       Impact factor: 5.750

5.  Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of 'soluble CD163' in plasma.

Authors:  Anders Etzerodt; Ronan M G Berg; Ronni R Plovsing; Morten N Andersen; Magali Bebien; Mohamed Habbeddine; Toby Lawrence; Holger J Møller; Søren K Moestrup
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

6.  The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature.

Authors:  Logan Froese; Joshua Dian; Alwyn Gomez; Bertram Unger; Frederick A Zeiler
Journal:  Pharmacol Res Perspect       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.